TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. - Archive ouverte HAL Access content directly
Journal Articles American Journal of Cancer Research Year : 2012

TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.

(1) , (1) , (1) , (1) , (1)
1

Abstract

Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL/TNFSF10) has been reported to specifically induce malignant cell death being relatively nontoxic to normal cells. Since its identification 15 years ago, the antitumor activity and therapeutic value of TRAIL have been extensively studied. Five receptors quickly emerged, two of them being able to induce programmed cell death in tumor cells. This review takes a comprehensive look at this ligand and its receptors, and its potential role in primary bone tumors (osteosarcoma and Ewing's sarcoma) therapy. The main limit of clinical use of TRAIL being the innate or acquired resistance mechanisms, different possibilities to sensitize resistant cells are discussed in this review, together with the impact of bone microenvironment in the regulation of TRAIL activity.
Fichier principal
Vignette du fichier
ajcr0000088.pdf (3.22 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-00667881 , version 1 (08-02-2012)

Identifiers

  • HAL Id : inserm-00667881 , version 1
  • PUBMED : 22206045

Cite

Gaëlle Picarda, Valérie Trichet, Stéphane Téletchéa, Dominique Heymann, Françoise Rédini. TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.. American Journal of Cancer Research, 2012, 2 (1), pp.45-64. ⟨inserm-00667881⟩
100 View
373 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More